Monitoring made easy— for you and your Ph+ CML patients Dear [NAME], Try IS RQ-PCR for free   Download request form IS RQ-PCR is the blood test that gives you a deeper look at your Ph+ CML patients’ BCR-ABL levels, helping you to detect early trends in their response status.1 • RQ-PCR is the most sensitive test available—providing the most precise measure of residual BCR-ABL, the cause of Ph+ CML1,2 • IS results are the only way to know for sure if your patient has achieved MMR—a recommended goal of therapy as early as 12 months2 New NCCN guidelines recommend monitoring with IS RQ-PCR every 3 months and achieving the following milestones at the months indicated2 Month Recommended response Sign of failure 3 <10% IS BCR-ABL mRNA or PCyR* >10% IS BCR-ABL mRNA or no PCyR* 12 MMR (<0.1% IS BCR-ABL mRNA) or CCyR* <PCyR 18 MMR (<0.1% IS BCR-ABL mRNA) with CCyR at 12 months* <CCyR 18+ No relapse Relapse (hematologic, cytogenetic, or 1-log increase in BCR-ABL mRNA and loss of MMR) *New NCCN recommendations, Version 1.2013. Treatment failure recommendations2 • Evaluate patient compliance and drug-drug interactions • Consider mutational analysis • Consider change of therapy, clinical trial, or stem cell transplant Here's how you can try free IS RQ-PCR testing for your patients through December 31, 2014 Download request form   Plus instructions and program details Ph+ CML, Philadelphia chromosome–positive chronic myeloid leukemia; IS, international scale; RQ-PCR, real-time quantitative polymerase chain reaction; MMR, major molecular response; NCCN, National Comprehensive Cancer Network; PCyR, partial cytogenetic response; CCyR, complete cytogenetic response. References: 1. Hughes T, Deininger M, Hochhaus A, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood. 2006;108(1):28-37. 2. The NCCN Chronic Myelogenous Leukemia Clinical Practice Guidelines in Oncology (Version 1.2013). © 2012 National Comprehensive Cancer Network, Inc. http://www.nccn.org. Accessed July 24, 2012. To view the most recent and complete version of the guidelines, go online to www.nccn.org. If you prefer not to receive any future promotional email communications from Novartis Pharmaceuticals Corporation, please click here. You may also submit your request in writing to: Novartis Pharmaceuticals Corporation One Health Plaza Customer Interaction Center  East Hanover, NJ 07936-1080 Please include “CML Partnership” in your communication. Novartis Pharmaceuticals Corporation East Hanover, New Jersey 07936-1080 © 2012 Novartis 9/12 CDE-1050321 Privacy Statement